Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data [0.03%]
实施药物基因组护照的障碍与促进因素：重复使用测序数据的经验教训
Anja H A Roelofsen,Loes Lindiwe Kreeftenberg,Carla G van El et al.
Anja H A Roelofsen et al.
Background: Pharmacogenetics uses individuals' genetic profiles to optimize drug treatment and prevent adverse reactions. One strategy to obtain information on pharmacogenes is to reuse sequencing data for a pharmacogenet...
Pharmacogenomics education among professional societies: assessing practices and future needs [0.03%]
专业学会中的药物基因教育：评估现行措施及未来需求
S L Bailey,D Messersmith,P E Empey
S L Bailey
Aims: To study the availability, perceived necessity, barriers, and preferred formats for pharmacogenomics (PGx) education disseminated to healthcare professionals by professional societies. ...
miR-369-3p regulates the drug resistance of lung cancer cells by targeting PTPN12 [0.03%]
miR-369-3p通过靶向PTPN12调节肺癌细胞的耐药性
Yan Wang,XiaoLi Wang,Jun Xu et al.
Yan Wang et al.
Objective: To explore the impact of low miR-369-3p expression on the resistance of PC-9 cells to osimertinib. Methods: The PC-9/AZD9291...
Association of SOD1 rs36232792 with opioid use disorder and a novel PCR-RFLP method for SOD2 rs5746136 [0.03%]
SOD1基因rs36232792多态性与阿片类物质使用障碍的相关性及辅酶Q10(SOD2)基因rs5746136多态性的PCR-RFLP检测方法的研究
Seval Küçükparmaksız,Dilek Kaya Akyüzlü,Selin Özkan Kotiloğlu et al.
Seval Küçükparmaksız et al.
Aim: The aim of this study is to find out the effect of SOD1 rs36232792 and SOD2 rs5746136 on the risk of opioid use disorder (OUD). Methods: ...
Implementation of clinical pharmacogenetic testing in medically underserved patients: a narrative review [0.03%]
实施临床药物基因组检测以解决医疗不足问题：综述性文章
Brian E Gawronski,Irina Fofanova,Angel M Miranda et al.
Brian E Gawronski et al.
As an emerging health technology, pharmacogenetic (PGx) testing has the capacity to improve medication therapy. However, implementation in medically underserved populations (MUPs) remains limited, which has the potential to increase healthc...
Pharmacogenetics to optimize immunosuppressant therapy in systemic lupus erythematosus: a scoping review [0.03%]
系统性红斑狼疮免疫抑制治疗的药物基因组学优化：系统综述
Alim Khodimul Rahmat,Irmasari,Zahrotun Nafiah et al.
Alim Khodimul Rahmat et al.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease requiring immunosuppressive medications to control symptoms and prevent organ damage. This review explores the influence of genetic polymorphisms on the pharmacokinetics and...
Survey of the utilization of genotype-guided tacrolimus management in United States solid organ transplant centers [0.03%]
美国实体器官移植中心关于基因型引导Tacrolimus管理应用的调查研究
Ashton Strother,Jeong M Park,Amy L Pasternak
Ashton Strother
Introduction: Genotype-guided tacrolimus management is not routine in clinical practice despite the availability of Clinical Pharmacogenetics Implementation Consortium dosing guidelines. Prior surveys have evaluated patie...
Michelle A Pressly,Robert Schuck,Padmaja Mummaneni et al.
Michelle A Pressly et al.
The development of polygenic risk scores (PRSs), which make use of genetic testing to assess an individual's risk of developing certain diseases or conditions based on collective genetic variant information, can be applied in drug developme...
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics [0.03%]
药物基因组学与罕见病：优化新药开发及个体化治疗
Youssef M Roman
Youssef M Roman
Pharmacogenomics (PGx) is an evolving field that integrates genetic information into clinical decision-making to optimize drug therapy and minimize adverse drug reactions (ADRs). Its application in rare disease (RD) drug development is prom...
Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting [0.03%]
细胞色素2C19基因多态性检测对颈动脉支架置入术后支架血栓形成风险的影响
Huai Wu Yuan,Xia Huang,Min Ying Pan et al.
Huai Wu Yuan et al.
Objective: We aimed to identify the impact of CYP2C19 polymorphism testing on clinical outcomes in patients who have undergone carotid artery stenting (CAS). ...